Premium
Mumbai-headquartered Wockhardt is charting a turnaround, riding on its promising antibiotic pipeline, led by a candidate codenamed WCK5222.
Rarely is a novel drug developed in India sought after by doctors to save patient lives if it is still at the trial stage. WCK5222 has already saved five patients’ lives here under a compassionate-use programme.
First Published: Jul 09 2023 | 2:18 PM IST